Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Relapsed Myeloid Neoplasm: early-phase trial registry

1 of 1 indexed Relapsed Myeloid Neoplasm trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Relapsed Myeloid Neoplasm: 1 US clinical trial tracked, 1 recruiting.

Relapsed Myeloid Neoplasm is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is University of Washington, running 1 of these trials.

Enrollment posture brief

Registry condition relapsed-myeloid-neoplasm

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Relapsed Myeloid Neoplas (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Relapsed Myeloid Neoplasm

Relapsed Myeloid Neoplasm lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Relapsed Myeloid Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Relapsed Myeloid Neoplasm is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Named interventions

Most-linked intervention names on Relapsed Myeloid Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Mitoxantrone Drug
1 trials
Cytarabine Drug
1 trials
Recombinant Granulocyte Colony-Stimulating Factor Biological
1 trials
Cladribine Drug
1 trials
Venetoclax Drug
1 trials

US sites by state

Facility locations filed on Relapsed Myeloid Neoplasm trials. A trial with sites in several states counts in each.

Washington 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Relapsed Myeloid Neoplasm page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Relapsed Myeloid Neoplasm condition card totals 1 registered trials; most-linked intervention Mitoxantrone; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.